Pain Assessment and Management

Dr. Hamidreza Mahaseni Aghdam Oral & Maxillofacial Surgeon **Determination of Pain**

Pain Management Approach

NEUROANATOMY AND PATHOPHYSIOLOGY OF PAIN

OPIOID ANALGESICS

LOCAL ANESTHETICS

NONOPIOID MEDIATED ANALGESIA

Perioperative pain control considerations

Pain Management Policy

All patients must have effective pain management

Appropriate screening and pain assessment

Documentation

Care and treatment

Pain education

Patient self report of pain must be source of assessment whenever possible

Patient's acceptable level of pain must guide treatment

Determination of Pain

Patient self report of pain must be source of assessment whenever possible

Patient's acceptable level of pain must guide treatment

If the patient is unable to self report, assessment strategies should include Observable behaviors (facial expressions, body movements, crying) physiological measures (heart rate and blood pressure).

What is Pain?

"An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage."

International Association for the Study of Pain (Merskey, 1979)

Pain is always subjective.

The patient's self-report of pain is the single most reliable indicator of pain.

The clinician must accept the patient's self report of pain.

Acute Pain

Acute pain presents most often with a clear cause, relatively brief in duration and subsides as healing takes place.

Acute pain is often accompanied by observable objective signs of pain

- increased pulse rate
- increased blood pressure
- Non-verbal signs and symptoms such as facial expressions and tense muscles.

Chronic Pain

Pain that is persistent and recurrent.

When pain persists, it serves no useful purpose and may dramatically decrease the quality of life and function.

Chronic pain rarely has any observable or behavioral signs although persons may appear anxious or depressed.

Pain Assessment

Initial Pain Assessment should include:

Location(s)

Intensity

Sensory quality

Alleviating and aggravating factors

Any new onset of pain requires a new comprehensive pain assessment.

Pain Management Approach

Should be interdisciplinary and multimodal.

Care is individualized and may depend on:

Pain source and intensity

Patient's age

Developmental, physical, emotional and cognitive status

Cultural beliefs

Treatment preferences

Concurrent medical conditions

Multimodal Analgesia

This term describes the use of multiple modalities that are used to provide pain relief with various parts of the pain pathway targeted.

Decreased dependence on single modality agents decreases the risk of side effects. May include

- Pharmacological (opioids, NSAIDS, gabapentanoids)
- Relaxation techniques (biofeedback, deep breathing)
- Regional analgesia (nerve blocks, epidural catheters)

Treatments May Include

NON-PHARMACOLOGIC METHODS

- Heat/cold
- Relaxation
- Distraction
- Acupressure/acupuncture

PHARMACOLOGIC METHODS

NSAIDS

Anti-seizure medications

Anti-depressants

Opioid analgesics

Local anesthetics

Neurolytics

Acute vs. Chronic Pain Management

ACUTE PAIN

Most often treated with:

NSAIDS

Opioids

Local anesthetics

Splinting

Positioning changes

Ice

CHRONIC PAIN

Most often treated with:

Anti-seizure medications

Anti-depressant medications

NSAIDS

Implantable devices

Psychological therapy

Acupuncture


When all else fails and benefits outweigh risks

Opioids

Management of acute pain

Nociception is the electrical transmission of a noxious stimulus from a site of injury to higher brain centers.

Following tissue damage outside of the craniofacial region, free nerve endings present in peripheral tissue are stimulated by mechanical, thermal, and chemical means.



A-delta fibers:

are lightly myelinated

have a larger diameter

are fast conducting

They are primarily activated by <u>mechanical</u> stimuli and are characterized by <u>sharp</u>, <u>stabbing</u>, and <u>shooting</u> sensations.

C fibers:


have a smaller diameter

are unmyelinated

transmit impulses at a slower rate


They are activated by <u>mechanical</u>, <u>chemical</u>, and <u>thermal</u> stimuli, and are associated with <u>dull</u> pains.

After synapsing with second order neurons in the dorsal horn, the impulse then crosses to the contralateral ascending spinothalamic tract.




Then it travels to the thalamus.

From the thalamus, the impulse travels to somatosensory cortex and limbic system.



The transmission of this impulse may also be affected by descending pain-modifying pathways from the cerebral cortex, midbrain, and brainstem.




The main sensory nerve of the orofacial region is the trigeminal nerve (cranial nerve V).

There are also some tissues in the craniofacial region receiving afferent sensory innervation from other cranial nerves (cranial nerves VII, IX, X, and XII) and branches of the upper cervical spinal nerves (C1, C2, C3).


After synapsing in the VBSNC, the impulse travels to the thalamus where it can be relayed to somatosensory cortex and the limbic system.

Descending modifying pathways are also present that can affect the transmission and sensation of pain.



Inflammation plays an important role in the development of postoperative pain.

As cells are disrupted, inflammatory mediators and metabolites are released into surrounding tissue beds.



Some of these factors can directly stimulate a nerve impulse in afferent pain fibers.

Prostaglandins, serve to sensitize nociceptors by lowering their activation thresholds. This leads to the hyperalgesia found in surgically altered tissue.

The natural by-products of **opium**, including morphine, codeine, and their semisynthetic derivatives, are known as opiates.

The activity of all opioids is related to their binding to a special set of receptors.

These <u>receptors</u> have been categorized into three groups: **mu**, **kappa**, and **delta**.

Agonists, such as morphine and codeine, elicit their analgesic effects by binding mu and kappa receptors.

Antagonists bind opioid receptors, but do not stimulate them.

<u>Naloxone</u>, a common narcotic reversal agent, is an opioid antagonist. Its ability to reverse the effects of opioid agonists is based on its higher binding affinity for opioid receptors.

Agonist-antagonist drugs act as agonists at one type of receptor and antagonists at others.

Pentazocine acts as an agonist at kappa receptors and an antagonist at mu receptors.

Their analgesic effect is generated mainly by the inhibition of nociceptive impulses in the CNS.

They have been found at various levels of the ascending pain pathway.

They have also been found in the midbrain and medulla, where they activate descending inhibitory pathways.

Binding at opioid receptors may lead to one of several biochemical results:

- 1) decrease in calcium influx at afferent nerve terminals leading to decreased presynaptic neurotransmitter release
- 2) increased potassium efflux leading to hyperpolarization of postsynaptic neurons and inhibition of impulse propagation
- 3) inhibition of GABAergic transmission in the brain-stem leading to the excitation of descending modulating circuits.

In addition to analgesia, activation of opioid receptors can lead to several undesirable effects.

Respiratory depression Nausea and vomiting Mental clouding Sedation Euphoria Constipation Hypotension Urinary retention Pruritus
























The activation of <u>mu</u> receptors in <u>respiratory centers</u> of the <u>brainstem</u> leads to <u>respiratory depression</u>.

This response is dose dependent and causes reductions in respiratory <u>rate</u> and <u>minute volume</u>.

This is the most serious side effect of opioid administration, and overdose can lead to respiratory arrest and death.

One of the more common unwanted effects of opioid use is nausea and vomiting.

This response is produced by the activation of neurons in the chemoreceptor trigger zone of the <u>medulla</u>.

Other CNS effects include mental clouding, sedation, and euphoria.

In the gastrointestinal (GI) system, opioids decrease gastric and intestinal motility leading to constipation.

Opioids cause arteriolar vasodilation and can result in orthostatic <u>hypotension</u>.

However, the decrease in cardiac demand caused by opioids can also be a benefit in patients experiencing angina or myocardial infarction.

Opioids also cause an increase in <u>smooth muscle</u> tone of the bladder and urinary sphincter leading to <u>urinary retention</u>.

Finally, **itching** may occur during opioid use as a result of the release of <u>histamine</u> from mast cells.

Oral administration is the most common route of administration.

Opioids absorbed in the GI tract are subject to first-pass hepatic metabolism. This limits their efficacy and increases inter-patient variability when administered orally.

Morphine is considered the prototype for all opioids.

Administration of morphine is indicated for <u>severe pain</u>, and thus its use in oral and maxillofacial surgery is limited.

Opioids have <u>no ceiling effect</u> for analgesia. Their administration is limited by the undesirable effects that occur as doses are increased.

Fentanyl is a fast-acting opioid that is approximately 100 times more potent than morphine.

It is indicated for <u>severe pain</u> and is a common agent used for conscious sedation in oral and maxillofacial surgical procedures.

Meperidine is 10 times less potent than morphine, has a slower onset, and lasts about twice as long as morphine and fentanyl.

Its use has generally fallen out of favor because of its <u>undesirable effects</u> (tachycardia, decreased myocardial contractility, mydriasis).

Normeperidine is a <u>neurotoxic</u> metabolite of meperidine.

It has been shown to cause dysphoria, tremors, and generalized seizures.

In addition, use of meperidine with monoamine oxidase inhibitors (MAOIs) can cause hypertensive crisis, hyperpyrexia, and cardiovascular collapse.

Antidepressant Classification	Generic Name	Trade Name
Monoamine oxidase inhibitors (MAOIs)	Isocarboxazid Phenelzine Selegiline transcutaneous Tranylcypromine	Marplan Nardil Emsam Parnate
Tricyclic antidepressant (TCAs)	Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Protriptyline Trimipramine	Elavil Anafranil Norpramin Sinequan Tofranil Aventyl HCL, Pamelor Vivactil Surmontil
Selective serotonin reuptake inhibitors (SSRIs)	Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline	Celexa Lexapro Prozac, Sarafem Fluvox Paxil, Pexeva Zoloft

Codeine is another <u>naturally occurring alkaloid</u> that is structurally <u>similar to morphine</u>. It is typically given in the oral form. Codeine is a weak mu agonist.

A small percentage of codeine is converted to morphine after administration.

In the oral form, codeine is about four times less potent than morphine.

Doses greater than 60 mg are not recommended because the side effects above this dose outweigh the analgesic benefits.

Hydrocodone and **oxycodone** are <u>semi-synthetic</u> opioids that are similar to morphine and codeine.

These drugs are available only in the oral formulation and are about 6.5 and 10 times more potent than codeine, respectively.

Propoxyphene is structurally <u>similar to methadone</u>, a compound typically prescribed to treat heroin dependence and addiction.

It has about two-thirds of the potency of codeine.

It also causes <u>cardiotoxicity</u>, <u>pulmonary edema</u>, and <u>arrythmias</u>.

It is therefore not generally considered a first-line choice for opioid analgesia. It may be of some use in patients that exhibit sensitivities to those medications.

Pentazocine is an opioid agonist-antagonist.

It exhibits mu antagonist activity and kappa agonist activity.

It has less respiratory depressive effects than the pure opioid agonists.

Because it antagonizes mu receptors, it can precipitate opioid withdrawal symptoms in patients concurrently taking mu agonists.

Tramadol is an analgesic drug marketed for treatment of moderate to severe pain.

It is a weak mu agonist.

Respiratory effects and abuse potential are minimal.

The efficacy of tramadol appears to be comparable with codeine and its oral combinations.

It has been associated with side effects such as headache, nausea, younging, somnolence, and seizures.

Analgesic	Dose (mg)	Dosing Interval (hr)	Comments
AGONIST	Dood (mg/	boomy intolvar (III)	Comments
Morphine	10-30	4	Standard analgesic dose used for potency comparisons
Codeine	60	3-4	Can be administered as a single agent or in combination with acetaminophen or aspirin
Hydrocodone	5-10	4-5	Only available in a combination formulation with either acetaminophen, aspirin or ibuprofen
Oxycodone	5-10	4-5	Only available in a combination formulation with either acetaminophen or aspirin
Propoxyphene MIXED AGONIST-ANTAGO	65-130 NIST	4-6	Weak analgesic properties
Pentazocine OTHER	50-100	4-6	Will precipitate an abstinence syndrome in patients dependent on opioids
Tramadol	50-100	4-6	Not available in a combination formulation; although currently unscheduled by the Drug Enforcement Administration, abuse potential exists

Local anesthesia is a loss of sensation in an area of the body caused by the depression of nerve ending excitation or the inhibition of nerve impulse conduction.

Amide local anesthetics are primarily metabolized in the liver.

Caution should be exercised when administering these drugs to patients with liver disease.

Lidocaine and mepivacaine, the most commonly used local anesthetics, are short-acting.

Used in conjunction with epinephrine, they block conduction for 3 to 5 hours.

Their use for postoperative pain is therefore limited.

The long-acting amide local anesthetics include bupivacaine and etidocaine.

The dental formulations of these drugs can block conduction for up to 8 to 12 hours.

Whenever using local anesthetics, the clinician should be cognizant of the maximum doses for each agent.

CNS and cardiovascular toxicity can result from overdose.

CNS depression from local anesthetic overdose typically manifests with <u>slurred</u> <u>speech</u>, <u>light-headed-ness</u>, <u>headache</u>, <u>blurred vision</u>, and <u>drowsiness</u>.

Generalized tonic-clonic seizures can also occur.

In the **cardiovascular system**, initial signs may include elevations in <u>heart rate</u>, <u>blood</u> <u>pressure</u>, and <u>respiratory rate</u>.


As levels of systemic local anesthetic increase, myocardial contractility is decreased, heart rate, blood pressure, and respiratory rate become depressed, and circulatory collapse can occur.

NONOPIOID MEDIATED ANALGESIA


The **inflammatory phase** of wound healing consists of release of <u>prostaglandins</u>, <u>histamine</u>, <u>kinins</u>, <u>leukotrienes</u>, and <u>substance</u> P.


Prostaglandin synthesis at the site of tissue injury enhances pain by increasing the <u>sensitization</u> and <u>reducing the activation threshold</u> of nociceptors, which is called **hyper-algesic** effect.

NONOPIOID MEDIATED ANALGESIA










































NSAIDs are effective <u>analgesic</u> agents with <u>antiinflammatory</u> and <u>antipyretic</u> activity.

They reduce pain, fever, and inflammation.

The **primary mechanism** of action is the <u>inhibition of cyclooxygenase</u> (COX) enzymes responsible for the conversion of arachidonic acid into prostaglandins.

Studies have determined that two different isoforms of COX exist, referred to as COX-1 and COX-2.

COX-1-mediated prostaglandins maintain homeostasis in the GI tract, kidney, heart, brain, and vasculature.

Prostaglandins <u>protect the GI mucosal</u> integrity by the stimulation and production of mucus and bicarbonate.

In the kidney, prostaglandins <u>regulate blood flow</u>, renin release, and renal tubular salt and water resorption.

In the circulatory system, prostaglandins regulate <u>vascular homeostasis</u> and platelet function.

Endogenous **prostaglandins mediated by COX-2** release the <u>inflammatory mediators</u> (including histamine, bradykinin, leukotrienes, and substance P) during tissue trauma.

These mediators result in increased <u>vasodilation</u> and <u>permeability</u> of the peripheral vasculature, <u>edema</u>, <u>erythema</u>, <u>hyperalgesia</u>, <u>loss of function</u>, and <u>pain</u>.

NSAIDs possess many advantages, including:

analgesic effects

antiinflammatory effects

antipyretic effects

do not result in sedation

do not result in respiratory depression

do not interfere with bowel and bladder function

they are relatively safe

they have a very low addiction rate


NONSTEROIDAL ANTIINFLAMMATORY DRUGS

Side effects are infrequent:

NSAIDs used as analgesic for acute postsurgical pain should be limited to 5 days

To minimize negative GI side effects, NSAIDs should be taken after meals or with food

Patients predisposed to GI disease should take NSAIDs with caution, especially if they have a history of alcohol abuse or peptic ulcer disease



Preoperative administration of nsaids

A state of hyperalgesia exists as a result when the local anesthetic wears off.

Patient discomfort subsequently increases during the lag time between NSAID administration and when therapeutic plasma concentrations of the analgesic are attained.

The administration of an NSAID preoperatively appears to maximize the usefulness of this drug class.

The efficacy of various NSAIDs is increased by administering the compound 30 minutes before the beginning of surgery.

Preoperative administration of nsaids

The agent of choice should be that with the fewest side effects.

Aspirin has demonstrated increased ecchymosis.

Diflunisal has demonstrated dry sockets.

Ibuprofen is suggested as the NSAID of choice for pretreatment.

Analgesic potency of this strategy does not appear to strengthen with doses of ibuprofen in excess of 400 mg in comparison with the increased undesirable side effects.

Preoperative administration of nsaids

BOX 6-2

Recommended Preoperative NSAID Protocol for Postoperative Pain Control

- Ibuprofen (400 mg) 30 min before the initiation of treatment
- · Benefits:
 - 1. Delayed onset of postoperative pain
 - 2. Decreased severity of postoperative pain
- · Precautions:
 - DO NOT use in patients for whom NSAIDs are contraindicated (e.g., NSAID allergy or sensitivity, GI ulcerations, renal disease).
 - Doses of ibuprofen in excess of 400 mg are associated with a greater incidence of unwanted side effects and have not been demonstrated to increase analgesic efficacy.

The **most common** adverse side effects of NSAIDs are **GI**, including <u>gastritis</u>, <u>ulceration</u>, and <u>bleeding</u>.

The potential for which increases with prolonged usage or <u>high daily doses</u> and <u>prior history</u> of such complications.

Attention has been paid to the potential for NSAIDs to increase the possibility of postoperative bleeding.

With the exception of aspirin, the <u>inhibition of platelet</u> function is reversible with NSAIDs.

DISADVANTAGES AND CONTRAINDICATIONS OF NSAIDS

The production of the powerful <u>platelet aggregating</u> agent, **thromboxane A2**, is indirectly <u>decreased</u> by NSAID inhibition of COX, increasing the likelihood for **GI bleeding**.

Great caution should be exercised when using NSAIDs during <u>pregnancy</u> or with the <u>elderly population</u> taking anticoagulants or corticosteroids.

Additional GI side effects are dyspepsia, peptic ulcer, dysphagia, and abdominal pain.

In the **genitourinary system**, NSAIDs adversely affect kidney function in patients with chronic renal disease.

They decrease renal blood flow and glomerular filtration rate.

NSAIDs are therefore **contraindicated** in patients with <u>severe renal disease</u> and may cause nephrotoxicity when taken chronically or in combination with other NSAIDs.

Other **non-Gl side effects** include:

Severe allergic reactions or <u>anaphylaxis</u> secondary to prostaglandin synthesis inhibition

Tachycardia

Edema

Dizziness

Headache

Increased liver enzymes

NSAIDs may diminish the antihypertensive effect of three classes of agents, including the <u>ACE inhibitors</u>, <u>B-blockers</u>, and <u>diuretics</u>, by inhibiting prostaglandin synthesis.

Because NSAID use for this effect is at least 7 to 8 days, their use **should be limited to 4 days** in patients taking antihypertensives.

BOX 6-3

NSAID Contraindications

- History of allergy or sensitivity to aspirin or NSAIDs
- · History of gastric ulcers
- Bleeding disorders (does not apply to acetaminophen)
- Renal disease
- Hepatic disease
- Pregnant or lactating females
- Asthma

Aspirin is perhaps the most common NSAID.

It has proven to be an effective <u>analgesic</u>, <u>antiinflammatory</u>, and <u>antipyretic</u>.

It has a low therapeutic ceiling; can cause gastric <u>ulcerations</u>, <u>perforations</u>, and <u>bleeding</u>; and inactivates platelets for their lifespan following consumption of the drug.

It can lead to the development of Reye's syndrome in children with viral infections.

Acetaminophen is similarly <u>common</u> to aspirin and similarly <u>safe</u>.

It provides effective relief for <u>mild pain</u>, can be combined with opioids for more serious pain, and has minimal short-term side effects.

It does not impact platelet function.

It does not possess the antiinflammatory properties.

It can cause **severe hepatic damage** (making it dangerous for alcohol abusers) and has a low therapeutic ceiling.

Ketorolac is an analgesic used commonly in conjunction with facial trauma, orthognathic surgery, and maxillofacial surgery.

It is **injectable** and has short-term side effects, such as <u>renal ischemia</u>, <u>GI perforation</u>, and <u>bleeding</u>, that can be lessened by limiting prescriptions to **less than 5 days**.

It has proven at least as effective as parenteral opioids in treating moderate to severe pain.

Celecoxib is currently the only COX-2 inhibitor up for commercial sale.

The drug only inhibits COX- 2-mediated prostaglandins, which cause inflammation, <u>limiting the negative effects</u> on the gastroprotective qualities of the COX-1 isoform.

COX-2 inhibitors can **disturb the hemodynamic balance** between the body's organs and adversely affects the <u>cardiovascular</u> system.

Trials have shown little difference in postoperative pain relief between COX-2 inhibitors and ibuprofen.

Generic	Pain Level	Dose (mg)	Interval (hr)	Maximum Dose/ 24 hr (mg)	Additional Comments
SALICYLIC ACID DERIVATIVES Aspirin	Mild	650-1000	4-6	4000	Increased risk of bleeding with excessive alcohol intake (≥3 drinks/day), avoid use with viral infections in children or teenagers, syndrome of asthma, rhinitis, and nasal polyps
Diflunisal	Mild to moderate	500	12	1500	1000-mg loading dose
ρ-AMINOPHENOL DERIVATIVES Acetaminophen	Mild	650-1000	4-6	4000	Increased risk of hepatotoxicity with excessive alcohol intake (≥3 drinks/day)
PROPIONIC ACID DERIVATIVES					
lbuprofen	Mild to moderate	400	4-6	3200	
Ketoprofen	Mild to moderate	25-50	6-8	300	
Naproxen sodium	Mild to moderate	275	6-8	1375	Start 550 mg then 275 mg every 6-8 hr
HETEROARYL ACETIC ACIDS Diclofenac	Mild to moderate	50	8	150	Loading dose up to 100 mg, total of 200 mg
Ketorolac	Moderate to severe	60 IM, 30 IV	Single dose	120	
		30 IM/IV	6	120	Transition from IV/IM to PO 20 mg, then every 4-6 hr; total duration of use ≤5 days
		20 then 10 PO	4-6	40	every 4-6 fir, total duration of use \$5 days
COXIBS					
Celecoxib	Mild to moderate	200	12	400	400-mg loading dose, then 200 mg if needed, selective COX-2 inhibitor

Corticosteroids act earlier in the cascade by suppressing arachidonic acid production, inhibiting prostaglandins and <u>leukotrienes</u>.

They also have **central antinociceptive properties** at the **spinal cord** level.

This leads to decreased pain and earlier ambulation, ability to consume food orally, and ultimately a shorter hospital stay.

For procedures expected to cause significant inflammation, methylprednisolone and other steroids have been prescribed.

A **disadvantage of concurrent use** of corticosteroids with NSAIDs is the significant increase in the risk of life-threatening <u>GI bleeding</u>.

Perioperative pain control considerations

Each oral and maxillofacial surgeon must anticipate a pain management strategy for individual patients.

Attenuation of the nociceptive impulses to the surgical insult while minimizing drug side effects, including nausea, diminished cognitive and motor function, and reduced patient anxiety, should be the goal of this strategy.

Postoperative pain management begins preoperatively.

Perioperative pain control considerations

BOX 6-4

Conclusions of Published Studies

- Half of all patients given conventional therapy for their pain do not get adequate relief. These patients continue to feel moderate to severe pain.
- Prescribing pain medication only "as needed" can result in prolonged delays because patients may delay asking for help.
- Aggressive prevention of pain is better than treatment because once established pain is more difficult to suppress.
- Patients have a right to treatment that includes prevention of pain and adequate pain relief. The surgeon needs to develop pain control plans before surgery and inform the patient what to expect in terms of pain after the surgery.
- Fears of postsurgical addiction to properly prescribed and administered opioids are generally groundless.

Perioperative pain control considerations

BOX 6-5

Key Patient Education Steps

- Describe the expected type of pain and its probable duration to decrease the uncertainty and fears of the unknown.
- Individualize the information for the patient.
- Discuss goals of pain management and how these goals help the patient's comfort, hasten recovery, and reduce complications.
- Reinforce the concept that pain prevention is important to good pain management.
 The patient should try to anticipate their pain medication requirements.
- Many drug and nondrug treatment options can be helpful in preventing and managing pain.
- Inform the patients of when and how to contact the surgeon about his or her pain.
- Parents of minor patients and the surgeon will decide as a team which treatments are best to manage their pain.
- Discuss treatment plan and choices including the schedule of medications that are appropriate to the patient.

Assessment and management of acute pain

In assessing and formulating a pain management plan, the clinician must consider the multiple factors that influence analgesic requirements.

BOX 6-6

Factors That Influence Analgesics Requirements

- Age of the patient. Very old or very young patients require smaller doses.
- Sex.
- Preoperative analgesic use.
- · Past history of poor pain management.
- Coexisting medical conditions, such as substance abuse, anxiety disorder, affective disorder, hepatic or renal impairments.
- · Cultural factors and personality.
- Preoperative patient education. Appropriate preoperative education can improve expectations, compliance, and ability to effectively interact with pain management techniques.
- Individual variations in response and pain threshold.
- Attitude of the clinical staff.

Assessment and management of acute pain

Type of Pain						
BL-SILL	Somatic Pain	Visceral	Neuropathic Pain			
Location	Localized	Generalized	Radiating or specific			
Patient Description	Pin prick, or stabbing, or sharp	Ache, or pressure, or sharp	Burning, or prickling, or tingling, or electric shock-like, or lancinating			
Mechanism of Pain	A-delta fiber activity; located in the periphery*	C Fiber activity; involved deeper innervation*	Dermatomal ‡ (peripheral), or non-dermatomal (central)			
Clinical Examples	 Superficial laceration Superficial burns Intramuscular injections, venous access Osseous surgery Stomatitis Extensive abrasion 	 Periosteum, joints, muscles Muscle spasm pain† Osseous surgery 	Trigeminal Avulsion neuralgia Post-traumatic neuralgia Peripheral neuropathy (diabetes, human immunodeficiency virus [HIV]) Herpetic neuralgia			
Most Responsive Treatments	 Acetaminophen Cold packs Corticosteroids Local anesthetic either topically or by infiltration Non-steroidal anti-inflammatory drugs (NSAIDs) Tactile stimulation 	Corticosteroids NSAIDs Opioid via any route Antispasmodics	Anticonvulsants Corticosteroids Neural blockade NSAIDs Opioids via any route Tricyclic antidepressants			

^{*} Most post-operative patients experience A-delta and C Fiber pain and respond best to narcotic of any route and NSAIDs.

[†] Muscle spasms may be less responsive to opioids. Respond best to antispasmodics, NSAIDs, benzodiazepines, baclofen.

[‡] Segmental distribution follows a dermatome chart. This traces the pathway of sensation to its nerve root.

Pre-emptive analgesia therapy

By preventing the sensitization of the CNS, which would normally amplify subsequent nociceptive input, one may reduce the severity of postoperative pain.

Giving an NSAID 30 minutes before a surgical visit improves the patient's postoperative comfort with delayed onset and decreased severity of postoperative pain.

During the postoperative period, <u>regular interval dosing</u> results in steady plasma concentration of the analgesic.

Pre-emptive analgesia therapy

Administration of <u>intraoperative ketorolac</u> has demonstrated a decrease in the amount and incidence of postoperative pain therapy.

The <u>long-acting local anesthetics</u> bupivacaine and etidocaine are preemptive in that they prevent neurotransmission of nociceptive stimuli for up to 8 to 12 hours.

<u>Corticosteroids</u> have been demonstrated to reduce opioid requirements in both orthognathic and third molar surgery. Steroids are recommended as a perioperative adjunct medication.

Patient-controlled analgesia

PCA is a method of <u>inpatient</u>, <u>self-administered</u> analgesia according to the surgeon's orders to control his or her pain.

A programmable infusion pump that delivers opioids at a continuous infusion rate (milligrams per hour) along with a patient-controlled demand bolus is administered via an IV.

A lock-out interval, when the pump will not allow more boluses to be administered, is programmed into the pump.

The primary **advantage** of the PCA is <u>patient convenience</u> and <u>preemptive pain control</u> because the patient controls when a dose of analgesia is given.